Associated Genetic Biomarkers
Cyclin-dependent kinase inhibitor 2C (CDKN2C, also known as p18) is a gene that encodes a protein that inhibits the activation of CDK 4 and CDK6. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as bone cancer, endometrial cancer, and intestinal cancer.
CDKN2C is altered in 0.74% of all cancers with malignant glioma, non-small cell lung carcinoma, colorectal adenocarcinoma, sarcoma, and breast carcinoma having the greatest prevalence of alterations .
The most common alterations in CDKN2C are CDKN2C Loss (0.22%), CDKN2C Amplification (0.11%), CDKN2C Deletion (0.01%), CDKN2C T88S (0.01%), and CDKN2C D17Gfs*7 (0.01%) .
CDKN2C status serves as an inclusion eligibility criteria in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials that contain CDKN2C status as an inclusion criterion, 2 are early phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).
Trials with CDKN2C status in the inclusion eligibility criteria most commonly target glioblastoma, glioma, malignant glioma, meningioma, and multiple myeloma .
The most frequent alterations to serve as inclusion eligibility criteria are CDKN2C Deletion, CDKN2C Loss, and CDKN2C Large Deletion .
Abemaciclib, cobimetinib, daratumumab, dexamethasone, and enasidenib are the most frequent therapies in trials with CDKN2C as an inclusion criteria .
Significance of CDKN2C in Diseases
Malignant Glioma +
CDKN2C is mutated in 4.8% of malignant glioma patients .
CDKN2C is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) .
Everolimus and ribociclib are the most frequent therapies in malignant glioma trials with CDKN2C alterations as inclusion criteria .
Multiple Myeloma +
CDKN2C is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Abemaciclib, cobimetinib, and daratumumab are the most frequent therapies in multiple myeloma trials with CDKN2C alterations as inclusion criteria .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.